Trial reportJapanese journal of ophthalmology2010
Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
Trial report in Japanese journal of ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.Japanese journal of ophthalmology · 2012Trial
- A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.TheScientificWorldJournal · 2012Trial
- Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement.ClinicoEconomics and outcomes research : CEOR · 2019Review
- Review
- Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.Clinical drug investigation · 2016Review
- Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.Ophthalmology and eye diseases · 2014Review
- Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%).
methodsTwenty-seven healthy volunteers were studied. After a 24-h IOP baseline measurement was taken, one ophthalmic solution was applied to the right eye daily for 7 days. The drug was then withdrawn for 2 weeks. The other agent was then applied to the left eye in the same manner. IOP was measured every 3 h for 24 h on the seventh day of treatment.
resultsThe 24-h IOP after 7 days' treatment with latanoprost decreased from 11.5 mmHg at baseline to 9.7 mmHg (-1.8 mmHg) and that with tafluprost from 11.8 to 9.8 mmHg (-1.9 mmHg). Tafluprost was statistically more effective after 24 h (P = 0.007; paired t test). The number of subjects with a 24-h mean IOP reduction of <10% was 8/27 (29.6%) with latanoprost versus 4/27 (14.8%) with tafluprost. The incidence of conjunctival hyperemia with latanoprost was 4/27 (14.8%) and that with tafluprost was 8/27 (29.6%).
conclusionThe overall efficacies of the two agents were not different, but tafluprost was associated with a greater reduction in IOP at 24 h after administration. Tafluprost showed a higher rate of conjunctival hyperemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.